Citations

Clear

77 citation(s) found for "Schwab, R J".

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel
Tibben, Bailey M. , Maillard, Maud , Pratt, Victoria M. , Moyer, Ann M. , Figueroa, Debbie M. , Gaedigk, Andrea , Stocco, Gabriele , Schwab, Matthias , Caudle, Kelly E. , Whirl-Carrillo, Michelle , Gaedigk, Andrea , Stocco, Gabriele , Schwab, Matthias , Caudle, Kelly E , Yang, Jun J.J. , Maillard, Maud , Figueroa, Debbie M , Whirl‐Carrillo, Michelle

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/cpt.70433 | PMID 42560154 Get It

The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles. These genes are critical for the metabolism of thiopurines, which are widely used in the treatment of cancer and autoimmune disorders. Standardized allele function assignment is essential for predicting metabolizer phenotypes and pharmacogenetics‐guided thiopurine dosing. The work presented here includes the first designation of decreased function alleles for both TPMT and NUDT15 , reflecting new clinical data that demonstrate partial loss of enzymatic activity and reduced dose tolerance. The panel also reclassified several alleles previously assigned uncertain or unknown function. The functional assignments were informed by a standardized framework incorporating clinical data, such as thiopurine tolerance and toxicity, as well as in vitro protein activity, ex vivo enzymatic measurements, and in silico variant effect prediction tools. These updates enhance the precision of genotype‐to‐phenotype mapping and support more personalized thiopurine therapy across diverse patient populations.
0589 Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep Apnea
Strollo, Patrick, Pho, Huy, Shah, Neomi, Schwab, R J, Somers, Virend, Gell, L., Farkas, Ron, Cronin, John, Patel, Sanjay, Somers, Virend K. , Taranto‐Montemurro, Luigi

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A261-A262

10.1093/sleep/zsag091.0588 Get It

Abstract Introduction AD109, an investigational oral anti-apneic neuromuscular modulator, combines in one tablet the novel antimuscarinic, aroxybutynin (2.5 mg), with the selective norepinephrine reuptake inhibitor, atomoxetine (75 mg). AD109 significantly improved the apnea-hypopnea index and oxygenation vs placebo (PBO) in two phase 3 clinical trials in OSA. This exploratory analysis evaluated concomitant administration of AD109 with glucagon-like peptide-1 receptor agonists (GLP-1 RA) on weight change in OSA. Methods SynAIRgy (NCT05813275; N=646) and LunAIRo (NCT05811247; N=660) were randomized, double-blinded, PBO-controlled, parallel-arm phase 3 trials of AD109 vs PBO in adults with mild-to-severe OSA (AHI >5) who failed or refused positive airway pressure therapy. Participants must have had a body mass index (BMI) 18.5–40 kg/m2 for males / 18.5–42 kg/m2 for females. Participants receiving GLP-1 RA for diabetes were permitted. Body weight was assessed throughout the trials. Results One-hundred and six participants were enrolled in the phase 3 trials taking a GLP-1 RA for diabetes (PBO+GLP-1 RA: n=48; AD109+GLP-1 RA: n=58). In participants receiving a GLP-1 RA with baseline BMI < 30, AD109 reduced weight by 2.7% (vs PBO: -1.4%, P=0.08) and 0.5% (vs PBO: 2.3%, P=0.60) at Week 26 and Week 51, respectively. In participants receiving a GLP-1 RA with baseline BMI 30 to 34.9, AD109 reduced weight by 0.9% (vs PBO: 1.2%, P=0.84) and 2.5% (vs PBO: 3.3%, P=0.85) at Week 26 and Week 51, respectively. In participants receiving a GLP-1 RA with baseline BMI ≥35, AD109 reduced weight by 5.5% (vs PBO: 0.9%, P=0.02) and 11.5% (vs PBO: 3.8%, P=0.04) at Week 26 and Week 51, respectively. Participants not receiving GLP-1 RA (n=979) showed smaller weight reductions across BMI classes; in participants with BMI ≥35, AD109 reduced weight by 1.4% (vs PBO: 0.2%, P=0.002) and 2.8% (vs PBO: 1.4%, P=0.19) at Week 26 and Week 51, respectively. Conclusion In this exploratory analysis using pooled data from SynAIRgy and LunAIRo, results indicate that participants with a baseline BMI ≥35 receiving AD109+GLP-1 RA experienced progressively greater weight loss over time relative to GLP-1 RA alone. Future studies are needed to further evaluate concomitant administration of AD109+GLP-1 RA in OSA. Support (if any) These studies were supported by Apnimed, Inc.
Abstract 94: Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors.
Brown, Erin L. , Zhang, W., Hashmi, Ayesha , Olelewe, Chibuzor, Viswanathan, Anushka , Kang, Minji , Jeon, Hyun Soo , Avagyan, Susanna , Bergsagel, Matteo , Schwab, Janella C. , Sachs, Chloe M., Qaium, Faridi , Bacchiocchi, Antonella , Cai, Qingyuan , Gentles, Andrew J. , Graham, Rondell, Orme, Jacob J. , Sznol, Mario, Halaban, Ruth, Chen, D., Newman, Aaron M. , Chaudhuri., Aadel A., Zhang, Wubing , Usmani, Abul , Earland, Noah , Chauhan, Pradeep S. , Steen, Chloé Beate , Alahi, Irfan , Semenkovich, Nicholas P. , Harris, Peter K , Lucas, Peter C. , Fields, Ryan C. , Mansfield, Aaron S. , Halaban, Ruth , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 94-94

10.1158/1538-7445.am2026-94 Get It

Abstract Background: Spatial cellular ecosystems in the tumor microenvironment (TME) form dynamic signaling hubs that critically influence cancer disease progression and response to therapy, including response to immune checkpoint inhibitors (ICIs). However, tumor sampling bias and the impracticality of acquiring serial tumor biopsies have made it challenging to profile the TME clinically. To address this challenge, we developed Liquid EcoTyper, a multi-analyte AI framework to quantify TME spatial cellular ecosystems—termed spatial ecotypes (SEs)—noninvasively from cell-free DNA (cfDNA) methylation data. Methods: In previous work, we discovered nine spatial ecotypes, including SEs associated with ICI response (e.g., SE7 with benefit, SE4 with resistance), and quantified them from 1,249 bulk tumor RNA-seq profiles of melanoma, non-small cell lung cancer (NSCLC), and bladder cancer (BC) patients (Cancer Res (2025) 85 (8_Supplement_1): 153). Here we trained Liquid EcoTyper, an interpretable deep learning model, to transfer SE profiling to cell-free DNA using CpG methylation profiles. Performance was quantified using simulated and real data, including methylation profiles (EM-seq) of plasma cfDNA paired with tumor biopsy-derived SE levels determined by EM-seq (n=20 pairs) or 10x Visium (n=15 pairs). Clinical outcome prediction was evaluated using pretreatment plasma from patients treated with ICI alone (n=78 melanoma pts), chemotherapy and ICI (n=25 NSCLC pts), and enfortumab vedotin and ICI (n=10 localized muscle-invasive BC (MIBC) pts). Tumor mutational burden (TMB), tumor PD-L1, or circulating tumor DNA (ctDNA) were profiled as a comparator where possible. Results: We observed striking concordance between plasma-derived SE levels and tumor biopsy-confirmed SE levels from the same patients, demonstrating that liquid biopsy analysis of cfDNA methylomes can recapitulate TME spatial biology. Underscoring specificity, no reliable SE signal was detectable from peripheral blood mononuclear cells. In pre-ICI plasma, liquid SE levels were significantly associated with ICI-based response (SE7) versus resistance (SE4) in patients with melanoma, NSCLC, and MIBC, with a mean cross-cancer area under the curve (AUC) of 0.87 for SE7 (range 0.8-0.97) and 0.81 for SE4 (range 0.76-0.85)—far surpassing TMB, tumor PD-L1, and ctDNA in evaluable patients, both in binary analyses of response and multivariable models of survival. Our results also showed potential to predict pathologic complete response in the neoadjuvant setting. Conclusion: Liquid EcoTyper is a scalable noninvasive AI-based framework for spatiotemporal assessment of the TME. By enabling TME-informed risk stratification without surgical biopsies, Liquid EcoTyper has potential to enable more precise and actionable decision making in patients with solid tumors. Citation Format: Erin L. Brown, Wubing Zhang, Abul Usmani, Noah Earland, Ayesha Hashmi, Chibuzor Olelewe, Anushka Viswanathan, Pradeep S. Chauhan, Minji Kang, Chloé B. Steen, Hyun Soo Jeon, Susanna Avagyan, Irfan Alahi, Nicholas P. Semenkovich, Matteo Bergsagel, Janella C. Schwab, Chloe M. Sachs, Faridi Qaium, Peter K. Harris, Antonella Bacchiocchi, Qingyuan Cai, Andrew J. Gentles, Rondell P. Graham, Peter C. Lucas, Ryan C. Fields, Jacob J. Orme, Aaron S. Mansfield, Mario Sznol, Ruth Halaban, David Y. Chen, Aaron M. Newman, Aadel A. Chaudhuri. Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 94.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update
Maillard, M., Schwab, Matthias, Whirl-Carrillo, Michelle, Moyer, AM , Suarez‐Kurtz, Guilherme , Pui, CH, Stein, C Michael, Klein, Teri E. , Spahn, Claire , Kwon, Sooyeon, Boer, Nanne K de, Ahmad, Tariq, Antillon-Klussmann, Federico Guillermo, Caudle, Kelly E. , Yeoh, Allen E J, Schmiegelow, K., Yang, Jun J, Schwab, Matthias , Maillard, Maud , Maillard, Maud , Schwab, Matthias , Whirl-Carrillo, Michelle , Caudle, Kelly E , Kato, Motohiro , Klein, Teri E , Whirl‐Carrillo, Michelle , Stein, C. Michael, Hartono, Juanda Leo , Ahmad, Tariq , Antillon‐Klussmann, Federico Guillermo, Kato, Motohiro , Yeoh, Allen Eng Juh

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 31, 2026 | Volume: 119 | Issue: 4 | Pages: 916-927

10.1002/cpt.70209 | PMID 41618934 Get It

Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard doses of thiopurines. Genetic variants in these genes are present in all world populations; however, their frequency varies by ancestry. In this updated guideline, we provide recommendations for adjusting starting doses of mercaptopurine, thioguanine, and azathioprine based on TPMT and NUDT15 genotypes, including for individuals with variants in both genes (updates on www.clinpgx.org ).
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Mürdter, Thomas E. , Schroth, Werner , Goetz, Matthew P. , Igel, Svitlana , Schaeffeler, Elke , Jäger, Simon , Loibl, Sibylle , Gerteis, Andreas , Pfaff, Lena , Bechtner, Christina , Wrobel, Denise , Bernhoft, Inger Marie , Bernhöft, Ilka , Bjelic-Radisic, Vesna, Burkhardt, Michael , Darsow, Maren , Deutsch, Gerhard, Ts, Dewitz, Dietz, Wolfgang, Eichbaum, Michael, Faust, Elke, Göhler, Thomas, Graßhoff, Sven-Thomas, Hackmann, John , Hänle, Claudia, Hartkopf, A, Heinrich, Bernhard, Kahl, Christoph, Kaltenecker, Gabriele, Kleine-Tebbe, Anke, Hc, Kolberg, Krauss, Thomas, Kuhn, Thomas , Kunz, Georg , Ligl-Löhner, Anette, Negwer, Martina, Rhein, Uwe, Rogmans, Gunther, Rom, Joachim , Stalzer, Gabriele, Stefek, Andrea , Strittmatter, Hans-Joachim, Terhaag, Jürgen, Uleer, Christoph , Wimmer-Freys, Karen, Zahm, Dirk-Michael, Fischer, Imma , Meisner, Christoph , Block, Michael , Tremmel, Roman , Igel, Svitlana , Schaeffeler, Elke , Jäger, Simon , Loibl, Sibylle , Gerteis, Andreas , Pfaff, Lena , Bechtner, Christina , Wrobel, Denise , Fischer, Imma , Meisner, Christoph , Block, Michael , Brauch, Hiltrud , Schwab, Matthias , Goetz, Matthew P , Tremmel, Roman , Bjelic-Radisic, Vesna , Burkhardt, Michael, Hartkopf, Andreas D , Heinrich, Bernhard , Kleine-Tebbe, Anke, Krauß, Thomas, Kühn, Thomas, Schmatloch, Sabine , Schwab, Matthias , Strittmatter, Hans-Joachim, Zahm, Dirk-Michael, Brauch, Hiltrud

Mayo Clinic

Clinical Cancer Research | October 2, 2025 | Volume: 31 | Issue: 23 | Pages: 4903-4911

10.1158/1078-0432.ccr-25-2103 | PMID 41036998 Get It

Abstract Purpose :Tamoxifen undergoes bioactivation to its active metabolite (Z)-endoxifen, which blocks estrogen-dependent breast tumor growth at high potency. We tested the feasibility and safety of supplementing standard tamoxifen therapy with low-dose (Z)-endoxifen in patients with breast cancer with compromised tamoxifen bioactivation. Patients and Methods :We conducted a prospective, interventional, three group randomized trial including 235 patients with hormone receptor–positive breast cancer who received standard tamoxifen therapy (20 mg/day). Patients were stratified by CYP2D6 genotype (n = 78), defining poor, intermediate, and normal metabolizers, or by baseline (Z)-endoxifen plasma concentration (n = 78), defining ≤15, 15 to 25, and ≥25 nmol/L. Co-treatment with (Z)-endoxifen 3 and 1.5 mg/day or placebo was performed, respectively. A control group (n = 79) received placebo regardless of metabolizer phenotype. The primary endpoint was the number of patients with (Z)-endoxifen levels >32 nmol/L after 6 weeks of treatment. Adverse events were continuously monitored. Results: A higher proportion of patients in both intervention groups achieved target concentrations >32 nmol/L compared with control (P < 0.0001). At 3 mg (Z)-endoxifen supplementation, 92.3% of CYP2D6 poor metabolizer patients and all patients with baseline (Z)-endoxifen ≤15 nmol/L achieved the target concentration. At 1.5 mg (Z)-endoxifen supplementation, 88% of CYP2D6 intermediate metabolizer patients and 95% of patients with 15 to 25 nmol/L baseline (Z)-endoxifen levels achieved the target concentration. Similar proportions of patients receiving (Z)-endoxifen (6/80, 7.5%) or placebo (8/155, 5.2%) experienced grade 3 adverse events. Conclusions: Adding low-dose (Z)-endoxifen to standard tamoxifen is safe and provides a new approach to personalized antiestrogen treatment for patients with low endoxifen plasma levels.
MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics
Greenberg, Steven M. , Albert, Marylin S., An, Hongyu , Arfanakis, Konstantinos , Evia, Arnold M , Caprihan, Arvind , Ford, Andria L. , Fornage, Myriam , Day, Gregory S. , Hinman, Jason D. , Kashani, Amir H. , Kramer, Joel H. , Lachner, Christian , Maillard, Pauline , Petersen, Ronald C. , Ringman, John M. , Savitz, Sean I. , Windham, B. Gwen, Zhang, Rong , Tuozzo, Carissa , Singh, Herpreet , Moy, Sue, Okey‐Ewurum, Vilma , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya, Helmer, Karl G. , Wruck, Lisa , Corriveau, Roderick A. , Jicha, Gregory A , Kashani, Amir H , Lachner, Christian , Lee, Jin-Moo , Liu, Peiying , Lu, Hanzhang , Maillard, Pauline , Petersen, Ronald C , Psaty, Bruce M , Ringman, John M , Rosenberg, Gary A. , Satizabal, Claudia L , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J J , Wilcock, Donna M , Tuozzo, Carissa , Singh, Herpreet , Okey-Ewurum, Vilma , Page, Courtney B , Mulder, Hillary , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya , Helmer, Karl G , Wruck, Lisa M , Day, Gregory S , Jicha, Gregory A. , Lee, Jin‐Moo , Liu, Peiying , Lu, Hanzhang , Psaty, Bruce M. , Satizábal, Claudia L. , Schneider, Julie A. , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J.J. , Wilcock, Donna M. , Mulder, Hillary , Schwab, Kristin

Mayo Clinic

Annals of Neurology | September 22, 2025 | Volume: 99 | Issue: 2 | Pages: 449-458

10.1002/ana.78040 | PMID 40977537 Get It

Objective To establish a framework for validating candidate biomarkers of cerebral small vessel diseases (SVD) associated with cognitive impairment and characterize individuals enrolled by the MarkVCID2 consortium under this framework. Methods Participants age 60 to 90 years were enrolled across 17 MarkVCID2 sites. Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impairment, subjective cognitive decline), defined risk factors (diabetes mellitus, advanced hypertension), and Black/African American, White, and Hispanic/Latino subgroups. Enrolled participants underwent baseline visits that included cognitive testing, multimodal magnetic resonance imaging (MRI), and biofluid collection. Provisional risk for SVD‐related cognitive decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors. Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate‐to‐severe white matter hyperintensities, microbleeds, or lacunes on baseline MRI. Results MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non‐Hispanic Black. Among enrollees, 44.8% were provisionally designated high‐risk. After baseline MRI, 48.5% were categorized as adjudicated high‐risk status, with substantial recategorization both from low‐ to high‐risk (primarily because of MRI lesions without SVD risk factors) and high‐ to low‐risk (primarily suspected cognitive impairment at screening not confirmed by baseline testing). Interpretation MarkVCID2 baseline data indicate successful enrollment of diverse individuals enriched in factors associated with SVD‐related cognitive decline. Changes over 3 years of longitudinal follow‐up will be analyzed to validate the candidate biomarkers for 2 projected contexts of use: subject selection (identifying likelihood of future SVD progression) and study outcome (efficiently measuring SVD progression). ANN NEUROL 2026;99:449–458
Ablative Techniques for the Management of Osseous Spine Metastases: A Narrative Review
Pennington, Zach , Morris, Jonathan M. , Elsamadicy, Aladine A. , Lo, Sheng-Fu Larry , Schwab, Joseph H. , Sciubba, Daniel M. , Pennington, Zach , Sciubba, Daniel

Mayo Clinic

Journal of Clinical Medicine | September 10, 2025 | Volume: 14 | Issue: 18 | Pages: 6358

10.3390/jcm14186358 | PMID 41010564 Get It

With continued improvements in systemic cancer therapies, there has been an increase in the survivorship of patients with spinal metastases. However, many patients with spinal metastases are frail and may not be able to tolerate the morbidity of open surgery. For these patients, percutaneous ablation techniques offer a minimally invasive approach that can facilitate local tumor control and pain relief. Here we describe the currently employed modalities—radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser interstitial thermal therapy (LITT)—summarize the clinical support for their use, and overview the relative risks and benefits for each. All these technologies offer to help improve local tumor control and improve oncologic pain associated with vertebral metastases, and they have become a staple of multidisciplinary spine metastasis care at many centers. As clinical experience with these technologies continues to grow, their use will likely become more widely adopted, and so understanding of their indications, risks, and benefits will become increasingly important to the practicing spine oncologist.
Abstract 153: High-resolution profiling of the tumor microenvironment with spatial ecotypes
Brown, Erin L. , Jeon, Hyun Soo , Semenkovich, Nicholas P. , Schwab, Janella C. , Sachs, Chloe M., Gungoren, Bilge , Qaium, Faridi , Mudd, Jacqueline L. , Cai, Qingyuan , Bacchiocchi, Antonella , Halaban, Ruth , Chaudhuri, Aadel A., Semenkovich, Nicholas P , Zhang, Wubing , Usmani, Abul , Earland, Noah , Alahi, Irfan , Steen, Chloé Beate , Harris, Peter K , Fields, Ryan C. , Sznol, Mario , Chen, David Y. , Chaudhuri, Aadel A. , Newman, Aaron M.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 153-153

10.1158/1538-7445.am2025-153 Get It

Background: Multicellular programs in the tumor microenvironment (TME) drive cancer pathogenesis and response to therapy but remain challenging to identify and profile clinically. Here, we present Spatial EcoTyper, a multimodal machine learning framework for large-scale profiling of spatially dependent cell states and multicellular ecosystems, termed spatial ecotypes (SEs). Methods and Findings: By integrating five million single-cell and spot-level spatial transcriptomes from 10 diverse human neoplasms, including carcinomas and melanomas, we identified a rich tapestry of conserved regional plasticity across nine TME cell types. We then applied Spatial EcoTyper to deeply dissect these data, revealing nine novel SEs with broad conservation - each with unique biology, TME cell states, geospatial features, and clinical outcome associations. SEs were linked to specific biogeographic domains, including the tumor core, margin, and adjacent stroma, and were remarkably well-validated in 235 held-out tumor samples profiled by either single-cell RNA sequencing, sequencing-based spatial transcriptomics (10x Visium), or high-resolution imaging-based spatial transcriptomics (Vizgen MERSCOPE and NanoString CosMx). By deconvolving SEs from over 1,200 bulk tumor RNA-seq profiles, we discovered striking associations between SE levels and response to immune checkpoint inhibitors (ICIs), outperforming nearly 40 potential correlates of ICI response, including previously described signatures of tertiary lymphoid structures and tumor tissue PD-L1 expression. Notably, baseline levels of a proinflammatory SE - localized to the tumor core and defined by a hub of unique T cell, macrophage, fibroblast, and endothelial cell states - strongly forecasted ICI benefit, while another SE - localized to the tumor margin and defined by myofibroblast and hypoxia-associated endothelial cell states - portended ICI resistance. Conclusion: Our data reveal fundamental units of TME organization and demonstrate a platform for large-scale profiling of spatial cellular ecosystems in any tissue, with implications for improved forecasting of immunotherapy response and the development of novel therapeutic strategies. Citation Format: Wubing Zhang,Erin L. Brown,Abul Usmani,Noah Earland,Hyun Soo Jeon,Irfan Alahi,Nicholas P. Semenkovich,Janella C. Schwab,Chloé B. Steen,Chloe M. Sachs,Bilge Gungoren,Faridi Qaium,Peter K. Harris,Jacqueline Mudd,Qingyuan Cai,Antonella Bacchiocchi,Ryan C. Fields,Mario Sznol,Ruth Halaban,David Y. Chen,Aadel A. Chaudhuri,Aaron M. Newman. High-resolution profiling of the tumor microenvironment with spatial ecotypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 153.
Cerebrovascular reactivity (CVR) MRI as a biomarker for cerebral small vessel disease (SVD) related cognitive decline: Multi‐site validation in the MarkVCID Consortium
Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Lucke, Emma, Gold, Brian T. , Greenberg, Steven M. , Helmer, Karl G. , Kramer, Joel H. , Mulavelil, Rachel, Singh, Herpreet , Velarde, Angel G., Kalyani, Rita R. , Rosenberg, Paul B. , Albert, Marilyn , Liu, Peiying , Lin, Zixuan , Jiang, Dengrong , Pillai, Jay J. , Bauer, Christopher E. , Jann, Kay , Jicha, Gregory A. , Maillard, Pauline , Satizábal, Claudia L. , Schwab, Kristin , Seshadri, Sudha , Wang, Danny J.J. , Moghekar, Abhay , Yaşar, Sevil , Lu, Hanzhang

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089224 Get It

AbstractBackgroundCerebral small vessel disease (SVD) related vascular contributions represent a major factor contributing to cognitive decline and dementia (VCID) in older adults. However, there has not been a validated biomarker for the diagnosis and treatment monitoring of this condition. Recently, the US National Institute on Neurological Disorders and Stroke (NINDS) funded the MarkVCID Consortium to identify and validate clinical‐trial‐ready biomarkers for VCID. Cerebrovascular reactivity (CVR) MRI is one of the selected biomarkers that underwent multi‐site testing in the Consortium. The present study aimed to report the relationship between CVR and cognitive function at independent sites, based on a pre‐specified hypothesis.MethodCVR, the ability of cerebral small vessels to dilate upon stimulus, is thought to directly reflect physiological function of the brain microvasculature. Based on previous single‐site findings, the pre‐defined hypothesis was that CVR will be associated with the global cognitive function measured by Montreal Cognitive Assessment (MoCA) after adjusting for age, sex, and education, and this association will be observed in data collected and analyzed at each individual site.A total of 264 older participants from three sites were included (Table 1). Each site performed an identical CVR MRI procedure using 5% CO2 inhalation, and a standardized clinical and cognitive evaluation. Multi‐linear regression analysis was conducted on a site‐by‐site basis to examine the pre‐defined hypothesis.ResultGray‐matter CVR showed a positive association with MoCA score after adjustment for age, sex, and education, in which participants with higher CVR had higher MoCA scores. This relationship was reproduced at each site (Figure 1, p<0.05 for each), confirming our pre‐specified hypothesis.In the secondary analysis of all data together, higher gray‐matter CVR was found to be significantly associated with better executive function measure of item response theory (IRT) score (β=2.87, p=0.003).ConclusionThe present study evaluated the relationship between CVR and cognition in a multi‐center setting. CVR was found to be positively associated with global cognitive function measured by the MoCA, which was shown to be reproducible across different sites with diverse cohorts. These findings support the utility of CVR as a biomarker in future clinical trials of SVD and VCID.
TMIC-03. CARD9 BLOCKADE OFFERS A NEW OPPORTUNITY TO REPROGRAM TUMOR-ASSOCIATED MACROPHAGES IN GLIOBLASTOMA
Yerneni, Saigopalakrishna S. , Crentsil, Hannah E. , Debom, Gabriela Nogueira, Klei, Linda R. , Smyers, Mei , Sneiderman, Chaim, Schwab, Kristina, Acharya, Rajesh , Wu, Yijen , Ekambaram, Prasanna , Hu, Dong , Gough, Pete J, Bertin, John , Bao, Riyue , McAllister‐Lucas, Linda M. , Azambuja, Juliana H. , Maurer, Lisa M. , Sneiderman, Chaim T. , Foley, Kevin P. , Melnick, Ari , Kohanbash, Gary , Lucas, Peter C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii297-viii297

10.1093/neuonc/noae165.1181 Get It

Abstract BACKGROUND Glioblastoma (GBM), one of the deadliest primary tumors of the central nervous system, is characterized by a highly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages and microglia (TAMs) are a dominant population of immune cells in the GBM TME and substantially contribute to immunosuppression, tumor progression, and treatment resistance. Elucidating the molecular mechanisms underlying TAM behavior is crucial to the development of effective immuno-therapeutic strategies for treating GBM. The adaptor protein, Caspase Recruitment Domain-containing protein 9 (CARD9) is primarily expressed in myeloid cells and its activation triggers assembly of the CARD9-BCL10-MALT1 (CBM) complex, which then promotes activation of NF-κB and/or MAPK pathways. The aim of this study was to investigate the role of the CBM complex in the GBM TME and assess its potential as a therapeutic target. METHODS/RESULTS In silico analyses revealed that GBM tumors demonstrate increased CARD9 and MALT1 expression in comparison to non-tumor brain tissue, with CARD9 expressed only within the myeloid compartment. Using co-culture, scratch wound, and transwell assays, we found that GBM tumor cells induce macrophage M2 polarization and migration via a mechanism that is dependent on CARD9/MALT1 signaling within macrophages. scRNA-Seq and flow-cytometric analysis of orthotopic syngeneic immunocompetent GBM tumor models revealed that the GBM TME is dominated by macrophages. Disruption of MALT1 protease activity within the TME leads to reduced tumor infiltration by immunosuppressive TAMs, remodeling of TAMs toward an immunoreactive anti-tumor phenotype, and improved survival of GBM-bearing mice. Additionally, we found that tumor growth was abrogated when GBM-bearing mice were treated with either a MALT1-protease inhibitor or a CARD9 inhibitor. CONCLUSIONS Our study suggests that blockade of the CARD9-MALT1 signaling axis impairs GBM-induced macrophage recruitment and M2 polarization and inhibits tumor progression. These findings nominate the CARD9-MALT1 signaling axis as a new target for TAM-directed immunotherapy for the treatment of GBM.